Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)

Table 3 Overall comparison of the frequency of patients with autoimmune diseases

	Proportion (%) of patients receiving co-therapies
	Before rituximab	During rituximab	After rituximab during follow-up^a
Immunosuppressives	98.1	41.2	78.6
Prednisolone	68.9	66.1	58.9
with glucocorticoid bolus therapy	17.0	1.25	1.6
Methylprednisolone	25.4	13.2	4.3
Methotrexate	22.1	6.9	8.9
Cyclophosphamide	36.2	8.15	3.2
Azathioprine	38.1	11.9	10.8
Mycophenolate mofetil	27.6	15.0	17.8
Intravenous Ig	17.0	3.4	5.1
Plasmapheresis	13.8	3.4	0.8
Other immunosuppressives	16.0	5.3	5.4

Overall comparison of the frequency of patients with autoimmune diseases receiving at least one administration of different types of therapies before, during and after rituximab therapy. Note, that certain immunosuppressive drugs were substantially different between individual diseases and only frequencies above 10% have been considered for this comparison.
^aFollow-up was as defined and recorded by the investigating physician.

ISSN: 1478-6362